178050 Implementation of a binational reporting protocol to identify, investigate, and report binational cases in the California border counties, 2005-2007

Tuesday, October 28, 2008: 1:05 PM

Martha Vázquez-Erlbeck, MD, MPH , California Office of Binational Border Health, California Department of Public Health, San Diego, CA
Alba E. Phippard, MPH , Border Infectious Disease Surveillance Program, San Diego County Health and Human Services Agency, Office of Border Health, MS P575, San Diego, CA
Maria-Teresa Bonafonte, PhD, MPH, MS , HealthCalifornia Department of Public Health/UCSD, California Office of Binational Border, San Diego, CA
Azarnoush Maroufi, MPH , Community Epidemiology, Health & Human Services Agency, County of San Diego, San Diego, CA
Angélica Pon Méndez, MD , Epidemiology Department, State of Baja California Department of Public Health, Mexicali, Baja California, Mexico
Paula Kriner, MPH , Imperial County Public Health Department, El Centro, CA
Karla Lopez, MD , Imperial County Public Health Department, El Centro, CA
Alfonso Rodriguez-Lainz, PhD, DVM, MPVM , California Office of Binational Border Health, California Department of Public Health, San Diego, CA
Michele Ginsberg, MD , Community Epidemiology, Health & Human Services Agency, County of San Diego, San Diego, CA
Background: California and Baja California seek strategies to address shared public health issues in the border region. Millions of border crossings occur every year, presenting a challenge to report infectious disease cases. A binational case is a patient or contact who traveled or resided in a neighboring state during exposure or incubation period or acquired the infection from a product, and the investigation requires collaboration of both countries. Objective: To develop a joint protocol between California-Baja California for the identification and follow-up of binational cases, and to describe binational cases identified in San Diego and Imperial counties during 2005-2007. Methods: Agreements, policies, and epidemiological surveillance systems for all jurisdictions were reviewed. Meetings were convened with local and state health authorities on both sides of the border to review surveillance and information-sharing strategies. In 2005, an informal protocol for the identification and notification of binational cases was implemented in California border counties. Results: San Diego County reported 14, 68, and 71 binational cases in 2005, 2006, and 2007, respectively. The majority (72%) were cases of Shigella, Campylobacter and Salmonella. In 2005-2007, Imperial County investigated 64 binational foodborne cases mostly Shigella, Campylobacter, and Salmonella and three binational outbreaks. Notifiable binational cases were reported by telephone and electronically to local and state epidemiologists in Baja California. Conclusions: Use of the binational case definition increased the number of cases identified by San Diego and Imperial counties. A formal implementation of a binational reporting protocol is required to enhance surveillance systems in California-Baja California.

Learning Objectives:
1. Participants will be able to describe the reporting system between San Diego and Imperial County to Baja California. 2. Participants will be able to describe the most frequent types of binational infectious disease cases in the California-Baja California border region. 3. Participants will be able to describe the public health benefit of implementing a binational surveillance and case reporting system between California and Baja California.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am the Border Epidemiologist for the Early Warning Infectious Disease Surveillance Program from the Infectious Disease Section of the Office of Binational Border Health from the California Department of Public Health. I am responsible to report and follow up, binational cases identified in San Diego County to the state epidemiologist in Baja California
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.